Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0148 • ACR Convergence 2025
Air Pollution as a Trigger for Flares in Chronic Inflammatory Rheumatic Diseases: a Prospective Single-Center Study in the South of France
Coralie Cruzel¹, antonio Iannelli², Alexandre Armengaud³, Sonia Oppo³, Marie Charlotte Trojani⁴, Stephanie Ferrero⁴, Veronique Breuil⁴, Eric Fontas⁵, Christian Roux⁴ and Clément Viala⁴, ¹². Department of Clinical Research, Cimiez Hospital, CHU Nice, Université Côte d'Azur, Nice, France, France, France, ²³. Centre Hospitalier Universitaire de Nice-Digestive Surgery and Liver Transplantation Unit, Archet ² Hospital, ⁰⁶²⁰² Nice, France., NIce, France, ³¹. University Cote d’Azur, Rheumatology department, CHU Nice, France, Marseille, France, ⁴¹. University Cote d’Azur, Rheumatology department, CHU Nice, France, NIce, France, ⁵². Department of Clinical Research, Cimiez Hospital, CHU Nice, Université Côte d'Azur, Nice, France, NIce, France
Background/Purpose: Rheumatoid arthritis (RA) and spondyloarthritis (SpA), are chronic inflammatory rheumatic diseases. Despite significant advancements in their management through novel therapies, some patients continue to…
Abstract Number: 0081 • ACR Convergence 2025
Trans-endothelial Trafficking of Fibroblast-like Synoviocytes Amplifies Synovial Inflammation in Rheumatoid Arthritis
Jaeyeon Kim¹, Sanaz Panahandeh², Hieu Nguyen³, Kainat Mian⁴, Hadijat Makinde⁴, Kyoung Jae Won⁵, Arminja Kettenbach³, Harris R Perlman⁴, Costantino Pitzalis⁶ and Nunzio Bottini⁷, ¹Cedars Sinai Medical Center, Los Angeles, CA, ²Cedars-Sinai Medical Center, Los Angeles, ³Geisel School of Medicine at Dartmouth, Lebanon, NH, ⁴Northwestern University, Chicago, IL, ⁵Cedars-Sinai Medical Center, Los Angeles, CA, ⁶QMUL, Bromley Kent, United Kingdom, ⁷Cedars Sinai Medical Center, Beverly Hills, CA
Background/Purpose: The discovery of circulating fibroblast-like synoviocyte (FLS), known as PRIME cells, in RA patients suggests that synovial FLS may enter the circulation through blood…
Abstract Number: 0061 • ACR Convergence 2025
IL-22 Contributes to Autoantibody-induced Arthritis Via Modulation of Inflammatory Cytokine and Chemokine Expression in the Inflamed Synovium of a Murine Model
Shinjiro Kaieda¹, Suzuna Sugi¹, Takuma Koga², Takashi Kinoshita¹ and Tomoaki Hoshino¹, ¹Kurume university School of Medicine, Kurume, Japan, ²Kurume Universty School of Medicine, Kurume, Japan
Background/Purpose: IL-22 is a key cytokine involved in modulating tissue responses during inflammation and is markedly upregulated in inflammatory diseases, such as psoriasis, inflammatory bowel…
Abstract Number: 2685 • ACR Convergence 2025
Assessing for Racial/Ethnic Variability in U.S.-FRAXTM Performance Among Older Adult Women with Rheumatoid Arthritis in the United States
Rachel Elam¹, Jing Li², Angel Paul³, Emma Kersey⁴, gabriela Schmajuk⁵, William Leslie⁶ and Laura Carbone¹, ¹Augusta University, Augusta, GA, ²University of California, San Francisco, San Francisco, CA, ³University of California San Francisco, Berkeley, CA, ⁴University of California San Francisco, San Francisco, CA, ⁵University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA, ⁶University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: Women with rheumatoid arthritis (RA) have 1.5- and 2-fold higher risk of major osteoporotic fracture (MOF: first of distal forearm, hip, humerus, or clinical…
Abstract Number: 2616 • ACR Convergence 2025
Real-World Implication of Clinical Disease Activity Index (CDAI) Utilization on Treatment Decisions and Clinical Outcomes in Rheumatoid Arthritis
Ryan Clark¹, Sally Almahdawi¹, Carolina Alvarez², Rumey Ishizawar³ and Thuyvan Phan⁴, ¹UNC Eshelman School of Pharmacy, Chapel Hill, NC, ²University of North Carolina at Chapel Hill, Miami, FL, ³UNC Division of Rheumatology, Allergy and Immunology and TARC, Chapel Hill, NC, ⁴UNC Health, Chapel Hill, NC
Background/Purpose: The University of North Carolina (UNC) Hospitals Rheumatology Clinic is utilizing the Clinical Disease Activity Index (CDAI) in patients with rheumatoid arthritis (RA) per…
Abstract Number: 2286 • ACR Convergence 2025
Association of Semaglutide Prescription with Improved Joint Outcomes in Rheumatoid Arthritis Patients
Faissal Stipho¹, Yazin Hindosh², Jonathan Sayegh², Akram Hindosh², Bassam Mitri² and Issa Batarseh¹, ¹Department of Internal Medicine, Banner University Medical Center / University of Arizona, Tucson, Arizona, Tucson, AZ, ²University of Arizona College of Medicine Tucson, Tucson, AZ
Background/Purpose: Rheumatoid Arthritis (RA) is an autoimmune disorder that results in immune dysfunction and swelling of major joints, leading to discomfort, pain, stiffness, and loss…
Abstract Number: 2269 • ACR Convergence 2025
Key factors in optimizing the dose of Baricitinib in rheumatoid arthritis: a study based on routine clinical practice and its therapeutic implications
Daniel Campos-Martin¹, Nerea Alcorta-Lorenzo², César Antonio Egües Dubuc², Luis Maria Lopez-Dominguez³, Lucia Otero⁴, Fernando Sánchez-Alonso⁵ and Joaquin Maria Belzunegui-Otano⁶, ¹Rheumatology Department, Donostia University Hospital, San Sebastian-Donostia, Pais Vasco, Spain, ²Rheumatology Department, Donostia University Hospital., San Sebastian, Spain, ³Rheumatology Department, Donostia University Hospital., San Sebastián, Pais Vasco, Spain, ⁴Spanish Society of Rheumatology, Madrid, Spain, ⁵Sociedad Española de Reumatología, Madrid, Spain, ⁶Rheumatology Department, Donostia University Hospital., San Sebastian-Donostia, Spain
Background/Purpose: Baricitinib, a selective JAK1/JAK2 inhibitor, has demonstrated efficacy in rheumatoid arthritis (RA). In patients with stable disease control for at least six months, reducing…
Abstract Number: 2253 • ACR Convergence 2025
Wrist-worn Wearable Device Data Can Be a New Digital Biomarker For Disease Activity In Rheumatoid Arthritis: a Multicenter Single-arm Prospective Study
Misako Higashida-Konishi¹, Keisuke Izumi², Shuntaro Saito Saito³, Hiroki Tabata⁴, Satoshi Hama⁴, Tatsuhiro Oshige⁴, Yutaka Okano⁴, Hisaji Oshima⁴, Katsuya Suzuki⁴, Jiro Sakamoto⁵, Toshikazu Fukami⁵, Kazumichi Minato⁵, Nobuhiko Kajio⁶, Yasushi Kondo³, Hiroaki Taguchi⁶ and Yuko Kaneko³, ¹NHO Tokyo Medical Center, Tokyo Meguroku, Japan, ²Division of Rheumatology, Department of Medicine, NHO Tokyo Medical Center/Keio University School of Medicine/TechDoctor, Inc., Tokyo, Japan, ³Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ⁴Division of Rheumatology, Department of Medicine, NHO Tokyo Medical Center, Tokyo, Japan, ⁵TechDoctor, Inc., Tokyo, Japan, ⁶Department of Rheumatology, Kawasaki Municipal Hospital, Kanagawa, Japan
Background/Purpose: Previous studies have estimated physical and mental states using wearable device data such as from smartwatches [1–3]. This study aimed to identify digital biomarkers…
Abstract Number: 2236 • ACR Convergence 2025
Treatment-induced autoantibodies in Rheumatoid Arthritis patients receiving anti-TNF inhibitors or JAK inhibitors
EVRIPIDIS KALTSONOUDIS¹, Nikolaos Kougkas², Panagiota Karagianni³, Tereza Memi⁴, Nikolaos Koletsos⁵ and Eleftherios Pelechas⁶, ¹Rheumatology Clinic, University of Ioannina, IOANNINA, Ioannina, Greece, ²⁴th Department of Internal Medicine, Aristotle University, Thessaloniki, Thessaloniki, Greece, ³BioAcuHealth.gr, Ioannina, Ioannina, Greece, ⁴University Hospital of Ioannina, Ioannina, Ioannina, Greece, ⁵School of Health Sciences, Faculty of Medicine, University of Ioannina, Department of Rheumatology, Ioannina, Greece, Ioannina, Ioannina, Greece, ⁶Hatzikosta General Hospital of Ioannina, Ioannina, Ioannina, Greece
Background/Purpose: Rheumatoid arthritis (RA) can coexist with other autoimmune disorders such as Sjögren’s syndrome and systemic lupus erythematosus (SLE). In these cases, the terms secondary…
Abstract Number: 2166 • ACR Convergence 2025
Clinical Disease Activity Index (CDAI) for Rheumatoid Arthritis: A Clinical Educational Workshop
Ahmed Rubia¹, Nancy Olsen², Saurav Suman³, Sharon Banks⁴, Shirley Albano Aluquin¹, Kristie Pepper⁵ and Rayford June⁶, ¹Penn State Milton S. Hershey Medical Cen, Hershey, PA, ²Penn State University/Milton S Hershey, Hershey, PA, ³Penn State Milton S. Hershey Medical Cen, Harrisburg, PA, ⁴Penn State Milton S. Hershey Medical Center, Hershey, PA, ⁵Penn State Milton S. Hershey Medical Cen, Lebanon, PA, ⁶Penn State College of Medicine/Lebanon VA Medical Center, Hummelstown, PA
Background/Purpose: The Clinical Disease Activity Index (CDAI) is one of six assessment measures for rheumatoid arthritis (RA) recommended for management of RA in clinical practice.…
Abstract Number: 1932 • ACR Convergence 2025
Evaluating a Potential Cause of Excess Lung Cancer Mortality in RA: An Analysis of Chest CT Imaging Frequency in RA
Rebecca Brooks¹, Sara Achenbach², Vanessa Kronzer¹, Bryant England³, Emily Leasure¹, Elena myasoedova¹, John Davis¹ and Cynthia Crowson⁴, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, ³University of Nebraska Medical Center, Omaha, NE, ⁴Mayo Clinic, Stewartvillle, MN
Background/Purpose: Recent studies have demonstrated that patients with RA are at an increased risk for the development of lung cancer and lung cancer related death.…
Abstract Number: 1750 • ACR Convergence 2025
Urinary Proteomic Signature Identifies Rheumatoid Arthritis Patients at Risk for Interstitial Lung Disease
Jia Shi¹, Xueting Yuan², Yafang Deng³, Chen Yu⁴, Nan Jiang⁵, Zhengguang Guo⁶, Christian Lood⁷, Mengtao Li⁵, Wei Sun⁶, Qian Wang⁵ and Xinping Tian⁵, ¹University of Washington, Seattle, WA, ²Peking Union Medical College Hospital (CAMS), Beijing, China (People's Republic), ³Peking Union Medical College Hospital. Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, Beijing, China (People's Republic), ⁴Peking Union Medical College Hospital, Dong Cheng Qu, Beijing, China (People's Republic), ⁵Peking Union Medical College Hospital, Beijing, Beijing, China (People's Republic), ⁶Peking Union Medical College, Beijing, China (People's Republic), ⁷University of Washington, Division of Rheumatology, Seattle
Background/Purpose: Interstitial lung disease (ILD) is a serious pulmonary complication of rheumatoid arthritis (RA), contributing significantly to morbidity and mortality. Non-invasive tools for identifying ILD…
Abstract Number: 1678 • ACR Convergence 2025
Abatacept in individuals at risk of developing rheumatoid arthritis: results from the Arthritis Prevention in the Pre-clinical Phase of RA with Abatacept Long Term Outcomes (ALTO) Study
Andrew Cope¹, Joana Vasconcelos¹, Marianna Jasenecova², Andrew Filer³, Karim Raza⁴, Sumera Qureshi¹, Maria Antonietta D'Agostino⁵, Iain McInnes⁶, Stefan Siebert⁶, John Isaacs⁷, Arthur Pratt⁸, Benjamin A. Fisher⁹, Christopher Buckley¹⁰, Paul Emery¹¹, Kulveer Mankia¹¹, Pauline Ho¹², MAYA BUCH¹³, Coziana Ciurtin¹⁴, Dirkjan van Schaardenburg¹⁵, Tom Huizinga¹⁶, René Toes¹⁶, Caroline Murphy¹ and A. Toby Prevost¹, ¹King's College London, London, United Kingdom, ²King's College London, London, ³The University of Birmingham, Birmingham, United Kingdom, ⁴University of Birmingham, Birmingham, United Kingdom, ⁵Division of Rheumatology and Clinical Immunology - Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ⁶University of Glasgow, Glasgow, United Kingdom, ⁷Newcastle University, Newcastle upon Tyne, United Kingdom, ⁸University of Newcastle, Newcastle, United Kingdom, ⁹King’s College London, London, UK; Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK, Birmingham, United Kingdom, ¹⁰University of Oxford, Oxford, United Kingdom, ¹¹University of Leeds, Leeds, England, United Kingdom, ¹²The Kellgren Centre for Rheumatology, Manchester Royal Infirmary, Manchester, United Kingdom, ¹³UNIVERSITY OF MANCHESTER, MANCHESTER, United Kingdom, ¹⁴University College London, London, ¹⁵Amsterdam UMC, Amsterdam, Netherlands, ¹⁶Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Clinical trials aimed at delaying or preventing rheumatoid arthritis (RA) in individuals at risk have been published with variable results. In the APIPPRA study,…
Abstract Number: 1374 • ACR Convergence 2025
AZD1163, a Novel Bispecific Human Antibody Targeting PAD2/4 Enzymes Responsible for Generating Citrullinated Protein Auto-antigens in Rheumatoid Arthritis, Demonstrates Dose-dependent Inhibition of Systemic PAD Activity in Healthy Volunteers
Susanne Prothon¹, Jacob Leander¹, Ulla Seppälä¹, Eduard Molins², Mia Collins¹, Nicholas White³, Ivonne Puente¹, Andre Santa Maria¹, Gary Sims⁴, David Han⁵, Obada Al Hamdan⁶, Ronald Goldwater⁷, Emon Khan⁸ and David Close⁹, ¹AstraZeneca, Gothenburg, Sweden, ²AstraZeneca, Barcelona, Spain, ³AstraZeneca, Cambridge, United Kingdom, ⁴AstraZeneca, Gaithersburg, ⁵Parexel, Los Angeles, ⁶Parexel, Berlin, Germany, ⁷Parexel, Baltimore, ⁸BioPharmaceuticals R&D, Late Respiratory and Immunology, AstraZeneca, Academy House, Cambridge, United Kingdom, ⁹AstraZeneca, Royston, United Kingdom
Background/Purpose: AZD1163 is a novel bispecific antibody that inhibits the activity of extracellular Peptidyl Arginine Deiminases (PADs) 2 and 4, enzymes responsible for protein citrullination…
Abstract Number: 1356 • ACR Convergence 2025
Use of (MSB11456), the first tocilizumab biosimilar approved for rheumatoid arthritis: 6-month data from an international observational study
Jonathan Kay¹, Eugen feist², Ernest Choy³, Joerg Kaufmann⁴, Ernest Wong⁵, Hector Corominas⁶, René-Marc Flipo⁷, Jérôme Avouac⁸, María América López Lasanta⁹, Joelle Monnet¹⁰, Peter Baker¹¹, Maria Romanova Michailidi¹², Fabrizio Dolfi¹¹ and Graziella Pourcel¹³, ¹UMass Chan Medical School, Worcester, MA, ²Helios Department of Rheumatology, Vogelsang-Gommern, Germany, ³Division of Infection and Immunity, CREATE Centre, Cardiff University, Cardiff, United Kingdom, ⁴NA, Ludwigsfelde, Germany, ⁵Portsmouth Hospitals University NHS Trust, Portsmouth, United Kingdom, ⁶Hospital de Sant Pau, Barcelona, Spain, ⁷Université de Lille, CHU Lille, Service de rhumatologie, Lille, France, Lille, France, ⁸Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France, ⁹Hospital Universitario Vall d´Hebron, Barcelona, Spain, ¹⁰Fresenius Kabi SwissBioSim, Eysins, Switzerland, ¹¹Fresenius Kabi Biopharma, Eysins, Switzerland, ¹²University of Geneva, Eysins, Switzerland, ¹³Fresenius Kabi Biopharma, Eyzins, France
Background/Purpose: Although most healthcare professionals are convinced of the quality, safety, and favorable economic impact of biosimilars, their routine use is not yet widespread. MSB11456…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].